What is the recommended nicotinamide adenine dinucleotide (NAD⁺) intravenous infusion protocol for an adult patient without severe renal or hepatic dysfunction, active infection, or allergy to NAD precursors?

NAD+ Intravenous Infusion Protocol

There is no established, evidence-based protocol for NAD+ IV infusion in clinical medicine, as no major medical guidelines or FDA-approved indications exist for this intervention. The available human data is limited to a single pilot study that used 3 μmol/min infused over 6 hours, but this was purely investigational and not validated for therapeutic use 1.

Current Evidence Limitations

Lack of Guideline Support

• No major medical societies (ACC/AHA, KDIGO, or other specialty organizations) have published guidelines recommending NAD+ IV infusion for any clinical indication 2
• The provided guidelines address entirely unrelated topics (supraventricular tachycardia, transplant nephrology, antifungal therapy) and contain no recommendations for NAD+ infusion protocols 2

Single Human Pilot Study Data

The only published human data on IV NAD+ infusion comes from a 2019 pilot study with critical findings 1:

• Infusion rate used: 3 μmol/min administered intravenously over 6 hours 1
• Plasma kinetics: NAD+ was rapidly and completely removed from plasma for at least the first 2 hours, with no detectable increase in plasma NAD+ or metabolites until after 2 hours 1
• Metabolic fate: The metabolite profile suggested NAD+ glycohydrolase and NAD+ pyrophosphatase activity, with urinary excretion of methylnicotinamide and NAD+ itself (but not nicotinamide) detected at 6 hours 1
• Critical limitation: This was purely a pharmacokinetic study with no assessment of clinical efficacy, safety monitoring protocols, or therapeutic outcomes 1

Oral NAD+ Precursors: The Evidence-Based Alternative

Established Safety and Efficacy

Oral supplementation with NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) represents the only evidence-based approach to augmenting NAD+ levels in humans 3, 4, 5:

• Nicotinamide riboside (NR) at 1,000 mg daily (500 mg twice daily) for 6 weeks is well-tolerated and effectively increases NAD+ levels in healthy middle-aged and older adults 4
• Oral NAD+ precursors are safe, tolerable, and can increase NAD+ abundance in multiple tissues 3
• These compounds have been studied in healthy adults, those with cardiometabolic risk factors, and various patient populations 3

Contrast with IV NAD+

• Oral precursors bypass the rapid plasma clearance observed with direct IV NAD+ infusion 1, 4
• The bioavailability and tissue uptake of oral precursors is superior to direct NAD+ administration based on available pharmacokinetic data 1, 4

Critical Clinical Caveats

Why IV NAD+ Lacks Clinical Validation

• Rapid clearance: Direct IV NAD+ is removed from plasma so quickly that therapeutic tissue levels may not be achieved 1
• Unknown dosing: The 3 μmol/min rate used in research has no established relationship to clinical efficacy or safety thresholds 1
• No outcome data: Zero published evidence exists demonstrating that IV NAD+ infusion improves morbidity, mortality, or quality of life in any patient population 1

Confusion with N-Acetylcysteine (NAC)

• The acronym "NAC" refers to N-acetylcysteine, not NAD+ 6
• N-acetylcysteine has established IV and oral protocols for acetaminophen overdose and contrast-induced nephropathy prevention, but these are completely unrelated to NAD+ supplementation 6

Preclinical vs. Clinical Evidence Gap

• While preclinical models show benefits of NAD+ augmentation in aging and disease states, initial clinical trials with oral NAD+ precursors have shown only modest effects in humans with obesity 5
• The translation from animal models to human clinical benefit remains unproven 3, 5

Recommendation for Clinical Practice

Do not use IV NAD+ infusion outside of IRB-approved research protocols. If NAD+ augmentation is desired for a patient, use oral nicotinamide riboside 500-1,000 mg daily, which has established safety data and demonstrated ability to increase tissue NAD+ levels 4. Any use of IV NAD+ would constitute experimental therapy without supporting evidence for efficacy or established safety monitoring parameters.